Guardian Pharmacy Services, Inc. (GRDN)
NYSE · Retail-Drug Stores And Proprietary Stores · Retail trade · CIK 1802255 · fiscal year ends in Dec
Closing price $40.63 on 30 Oct 2026; 52-week range $27.03 to $48.00.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $1.5B
- Revenue growth
- 10.3%
- Net income, last twelve months
- $65.9M
- Earnings per share
- $1.03
- Gross margin
- 21.6%
- Operating margin
- 5.8%
- Net margin
- 4.5%
- Return on equity
- 25.6%
- Market value
- $2.6B
- Price to earnings
- 39.4x
- Cash
- $89.8M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 63.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $1.4B | $72.7M | $49.2M | $0.78 | $86.8M | 10-K filed 11 Mar 2026 |
| FY2024 | 31 Dec 2024 | $1.2B | -$62.9M | -$110.0M | -$1.77 | $43.3M | 10-K filed 11 Mar 2026 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $351.8M | $21.9M | $0.34 |
| Q1 FY2026 | 31 Mar 2026 | $336.6M | $13.3M | $0.21 |
| Q4 FY2025 | 31 Dec 2025 | $397.6M | $20.9M | $0.33 |
| Q3 FY2025 | 30 Sep 2025 | $377.4M | $9.8M | $0.15 |
| Q2 FY2025 | 30 Jun 2025 | $344.3M | $9.0M | $0.14 |
| Q1 FY2025 | 31 Mar 2025 | $329.3M | $9.4M | $0.15 |
| Q4 FY2024 | 31 Dec 2024 | $338.6M | $11.9M | $0.19 |
| Q3 FY2024 | 30 Sep 2024 | $314.4M | -$122.0M | -$2.00 |
Company events
The newest 8-K filings of 24 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 10 Sep 2026 | 8-K | Other events | 8.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 22 Jun 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 28 May 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 7 May 2026 | 8-K | Shareholder vote | 5.07 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Mar 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 11 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Jan 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 10 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 14 Oct 2025 | 8-K | Other events | 8.01 |
| 18 Sep 2025 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 76 held.
| Filed | Form | Period |
|---|---|---|
| 10 Sep 2026 | 8-K | 10 Sep 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 22 Jun 2026 | 8-K | 22 Jun 2026 |
| 28 May 2026 | 8-K | 21 May 2026 |
| 7 May 2026 | 8-K | 5 May 2026 |
| 6 May 2026 | S-8 | – |
| 6 May 2026 | S-3ASR | – |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 26 Mar 2026 | DEFA14A | – |
| 26 Mar 2026 | DEF 14A | 5 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 20 Mar 2026 | Pharmacy Investors, Llc, Insider | Sale outside a trading plan | 827,636 | $29.68 | $24.6M | 1,035,928 | 24 Mar 2026 |
| 20 Mar 2026 | Morris David K, See Remarks | Sale outside a trading plan | 187,855 | $29.68 | $5.6M | 254,472 | 24 Mar 2026 |
| 20 Mar 2026 | Burke Fred, See Remarks | Sale outside a trading plan | 671,432 | $29.68 | $19.9M | 840,413 | 24 Mar 2026 |
| 20 Mar 2026 | Forbes Kendall, See Remarks | Sale outside a trading plan | 346,672 | $29.68 | $10.3M | 453,256 | 24 Mar 2026 |
| 20 Mar 2026 | Cardinal Equity Fund, L.P., Insider | Sale outside a trading plan | 275,728 | $29.68 | $8.2M | 345,123 | 24 Mar 2026 |
| 20 Mar 2026 | Salentine Thomas J Jr, Director | Sale outside a trading plan | 3,570,677 | $29.68 | $106.0M | 4,469,316 | 24 Mar 2026 |
| 20 Mar 2026 | Bindley Capital Partners I, Llc, 10% owner | Sale outside a trading plan | 3,570,677 | $29.68 | $106.0M | 4,469,316 | 24 Mar 2026 |
| 20 Mar 2026 | Ackerman John, Director | Sale outside a trading plan | 827,636 | $29.68 | $24.6M | 1,035,928 | 24 Mar 2026 |
| 20 Mar 2026 | Ackerman John, Director | Sale outside a trading plan | 275,728 | $29.68 | $8.2M | 345,123 | 24 Mar 2026 |
| 20 Mar 2026 | Bindley William E, Director | Sale outside a trading plan | 3,570,677 | $29.68 | $106.0M | 4,469,316 | 24 Mar 2026 |
| 3 Dec 2025 | Cosler Steven D, Director | Purchase | 3,370 | $29.61 | $99.8K | 24,984 | 5 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Sep 2026 | Bindley Capital Partners I, LLC | 13D amended | 26.4% | 16.7M |
| 6 May 2026 | FMR LLC | 13G | 6.5% | 2.4M |
| 24 Mar 2026 | Bindley Capital Partners I, LLC | 13D amended | 21.3% | 10.6M |
| 13 Feb 2026 | BROWN ADVISORY INC | 13G amended | 4.54% | 1.6M |
| 10 Feb 2026 | Wellington Management Group LLP | 13G amended | 3.1% | 1.1M |
| 21 Jan 2026 | BlackRock, Inc. | 13G amended | 4.2% | 1.5M |
| 14 Nov 2025 | J. Goldman & Co LP | 13G amended | 2.9% | 656.9K |
| 12 Nov 2025 | Wellington Management Group LLP | 13G | 5.03% | 1.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.4M | -3.91% | 5.31 |
| 30 Sep 2026 | 2.5M | +2.18% | 3.06 |
| 15 Sep 2026 | 2.4M | -20.21% | 3.73 |
| 31 Aug 2026 | 3.0M | +1.16% | 9.41 |
| 14 Aug 2026 | 3.0M | +5.42% | 7.4 |
| 31 Jul 2026 | 2.9M | +2.2% | 9.55 |
| 15 Jul 2026 | 2.8M | -9.65% | 7.13 |
| 30 Jun 2026 | 3.1M | -4.74% | 5.25 |
Funds that hold it
From each fund's latest Form 13F.
205 funds held it at 30 Jun 2026: 105 added and 54 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 3,241,612 | $135.7M | +882,255 |
| Wellington Management Group LLP | 1,729,032 | $72.4M | -36,087 |
| BlackRock, Inc. | 1,575,989 | $66.0M | -180,385 |
| Vanguard Capital Management LLC | 1,379,750 | $57.8M | +154,207 |
| Woodline Partners LP | 1,306,340 | $54.7M | +22 |
| Valiant Capital Management, L.P. | 1,186,658 | $49.7M | 0 |
| T. Rowe Price Investment Management, Inc. | 1,116,868 | $46.8M | +88,479 |
| Boston Partners | 983,868 | $40.8M | -33,815 |
| Franklin Resources Inc. | 966,206 | $40.5M | +13,254 |
| TimesSquare Capital Management, LLC | 951,637 | $39.8M | -125,837 |
Peers
Companies in the same industry.
- CVS Health Corp. (CVS): revenue $415.1B, market value $115.3B